We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+37.76%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4.9B
AUM Growth
+$644M
Cap. Flow
-$263M
Cap. Flow %
-5.37%
Top 10 Hldgs %
40.38%
Holding
132
New
23
Increased
22
Reduced
35
Closed
25
Avg Time Held Equity + Options
8.6 quarters
Top 10 Avg Time Held Equity + Options
7 quarters
Top 20 Avg Time Held Equity + Options
8.2 quarters
Avg Time Held Equity only
8.7 quarters
Top 10 Avg Time Held Equity only
7 quarters
Top 20 Avg Time Held Equity only
8.2 quarters

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$41.7M
2
BMY icon
Bristol-Myers Squibb
BMY
+$37.3M
3
ELV icon
Elevance Health
ELV
+$33.5M
4
HELP
Helus Pharma Inc. Common Stock
HELP
+$24.7M
5
BRKR icon
Bruker
BRKR
+$23.5M

Top Sells

Rank Stock Value
1
TERN icon
Terns Pharmaceuticals
TERN
+$125M
2
RNAM
Avidity Biosciences
RNAM
+$65.8M
3
EXAS icon
Exact Sciences
EXAS
+$51.6M
4
AXSM icon
Axsome Therapeutics
AXSM
+$38.9M
5
SIBN icon
SI-BONE Inc
SIBN
+$38M

Sector Composition

Rank Sector Weight
1 Healthcare 99.3%
2 Miscellaneous 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
TECX icon
76
Tectonic Therapeutic
TECX
$414M
$12M 0.24%
+574,600
New +$10.7M
2025 Q4
0 quarters
ALMS icon
77
Alumis Inc
ALMS
$850M
$10.8M 0.22%
1,102,730
-823,693
-43% -$5.75M
2025 Q2
2 quarters
BIOA icon
78
BioAge Labs
BIOA
$257M
$10.5M 0.21%
790,901
– –
2024 Q3
5 quarters
FOLD icon
79
DELISTED
Amicus Therapeutics
FOLD
$10.4M 0.21%
729,900
-915,500
-56% -$8.99M
2023 Q4
8 quarters
WHWK icon
80
Whitehawk Therapeutics
WHWK
$174M
$10.1M 0.21%
4,166,000
– –
2025 Q1
3 quarters
ACET icon
81
Adicet Bio
ACET
$49.1M
$8.66M 0.18%
1,027,944
+312,498
+44% +$3.45M
2018 Q1
31 quarters
RPTX icon
82
DELISTED
Repare Therapeutics
RPTX
$8.64M 0.18%
3,322,488
– –
2020 Q2
22 quarters
CELC icon
83
Celcuity
CELC
$3.12B
$8.54M 0.17%
85,664
+1,644
+2% +$135K
2025 Q3
1 quarter
JBIO icon
84
Jade Biosciences
JBIO
$867M
$8.2M 0.17%
531,163
– –
2025 Q2
2 quarters
KNSA icon
85
Kiniksa Pharmaceuticals
KNSA
$6.15B
$7.72M 0.16%
+187,199
New +$7.51M
2025 Q4
0 quarters
QTTB icon
86
Q32 Bio
QTTB
$237M
$7.48M 0.15%
2,252,987
– –
2024 Q1
7 quarters
PMVP icon
87
PMV Pharmaceuticals
PMVP
$71.1M
$6.22M 0.13%
4,975,291
-1,000,000
-17% -$1.34M
2020 Q3
21 quarters
KALV icon
88
DELISTED
KalVista Pharmaceuticals
KALV
$6.18M 0.13%
+382,400
New +$5.06M
2025 Q4
0 quarters
PHVS icon
89
Pharvaris
PHVS
$2.13B
$5.7M 0.12%
+205,400
New +$4.95M
2025 Q4
0 quarters
NSPR icon
90
InspireMD
NSPR
$24M
$5.58M 0.11%
3,133,405
+1,000,000
+47% +$2.08M
2023 Q2
10 quarters
INSM icon
91
Insmed
INSM
$21.3B
$4.42M 0.09%
25,400
+11,941
+89% +$2.18M
2024 Q4
4 quarters
PALI icon
92
Palisade Bio
PALI
$261M
$4.4M 0.09%
+1,871,420
New +$3.6M
2025 Q4
0 quarters
BCAX icon
93
Bicara Therapeutics
BCAX
$1.15B
$3.52M 0.07%
+209,100
New +$3.57M
2025 Q4
0 quarters
CGEM icon
94
Cullinan Oncology
CGEM
$914M
$2.79M 0.06%
270,006
-1,653,849
-86% -$14.9M
2021 Q1
19 quarters
CCCC icon
95
C4 Therapeutics
CCCC
$346M
$2.68M 0.05%
1,404,902
-3,830,244
-73% -$9.07M
2024 Q2
6 quarters
IMA icon
96
ImageneBio Inc
IMA
$48.2M
$2.61M 0.05%
378,556
– –
2021 Q1
19 quarters
ANRO icon
97
Alto Neuroscience
ANRO
$896M
$2.23M 0.05%
125,000
-125,000
-50% -$1.57M
2024 Q4
4 quarters
RVMD icon
98
Revolution Medicines
RVMD
$40.6B
$2.06M 0.04%
+25,900
New +$1.7M
2025 Q4
0 quarters
VTGN icon
99
VistaGen Therapeutics
VTGN
$9.49M
$2.03M 0.04%
3,060,000
– –
2025 Q3
1 quarter
OCUL icon
100
Ocular Therapeutix
OCUL
$1.62B
$1.91M 0.04%
+157,300
New +$1.91M
2025 Q4
0 quarters
2 3
4
5 6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q4 2025 Portfolio in Review

As of Q4 2025, OrbiMed held 132 positions worth $4.9B, up 15% from $4.26B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed withdrew a net $263M in Q4 2025, closing 25 positions and reducing 35 holdings. Its most notable exit was SI-BONE Inc, an estimated $38M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in Pfizer worth $41.2M.

  • OrbiMed's largest Q4 2025 buy was Pfizer: 1,652,900 shares worth $41.2M.
  • OrbiMed added most to RAPT Therapeutics in Q4 2025, an estimated $17.3M increase.
  • OrbiMed's biggest Q4 2025 reduction was Terns Pharmaceuticals, cutting an estimated $125M.
  • OrbiMed fully exited SI-BONE Inc in Q4 2025, selling an estimated $38M.
  • OrbiMed's ten largest holdings make up 40% of its $4.9B portfolio in Q4 2025.
  • OrbiMed opened 23 new positions and closed 25 in Q4 2025.
  • OrbiMed's portfolio value rose 15% quarter-over-quarter to $4.9B.

Based on OrbiMed's 13F filing for Q4 2025, filed 17 Feb 2026.